epirubicin + cyclophosphamide + fluorouracil + paclitaxel

Epirubicin + cyclophosphamide + fluorouracil + paclitaxel (often abbreviated as FEC-P or FEC-T) is a multi-agent cytotoxic chemotherapy regimen primarily employed in the neoadjuvant (pre-surgical) setting for breast cancer, particularly HER2-negative cases. The regimen combines four distinct small-molecule agents: epirubicin (an anthracycline topoisomerase II inhibitor), cyclophosphamide (an alkylating agent), fluorouracil (a pyrimidine antimetabolite), and paclitaxel (a taxane microtubule stabilizer). By targeting DNA replication, repair, and mitotic spindle assembly through multiple pathways, the combination aims to maximize tumor shrinkage and increase the likelihood of a pathological complete response (pCR). In clinical research, such as the Phase II BERNAQ trial, this regimen serves as a standard-of-care comparator against personalized chemotherapy approaches based on biomarkers like BRCA1 mRNA expression.

Other names

epirubicin + ciclofosfamide + fluorouracil + paclitaxelFEC followed by paclitaxelFEC-PFEC-T